Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer SK, Neurath M, Atreya R (2020)


Publication Type: Conference contribution

Publication year: 2020

Journal

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: S466-S467

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjz203.676

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Fischer, S., Mesfin, S.E., Klenske, E., Schmitt, H., Vitali, F., Hirschmann, S.,... Atreya, R. (2020). Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study. In JOURNAL OF CROHNS & COLITIS (pp. S466-S467). OXFORD: OXFORD UNIV PRESS.

MLA:

Fischer, Sören, et al. "Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2020. S466-S467.

BibTeX: Download